Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-QULIC-5-P1 SPECT Imaging in Prostate Cancer
NCT06419348Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 99mTc-QULIC-5-P1 in prostate cancer (PCa), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Diagnostic efficacy at 15 days. Started May 2024; status: recruiting.
02
Drugs
99mTc-QULIC-5-P1
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06419348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06419348.